Unbalanced randomization influences placebo response: Scientific versus ethical issues around the use of placebo in migraine trials

Cephalalgia

Volumn 19, Issue 8, 1999, Pages 699-700

  Diener, H C ^a   Dowson, A J ^b   Ferrari, M ^c   Nappi, G ^d   Tfelt Hansen, P ^e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PAVIA   (Italy)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ETHICS; METHODOLOGY; MIGRAINE; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

DOUBLE-BLIND METHOD; ETHICS, MEDICAL; HUMANS; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; PLACEBOS; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0032733161     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1999.019008699.x     Document Type: Article

References (7)

1. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia 1991;11:1-12
2. 1B/1D receptor agonists. Neurology 1997;48 Suppl 3:S21-4
3. Geraud G, Oleson J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Sweet R, for the multinational oral zolmitriptan and sumatriptan comparative study group. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (forthcoming)
4. 1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998;5:535-43
5. Rapoport AM, Ramadan NM, Adelmann JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology 1997;49:1210-8
6. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of the 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997;9:1219-25
7. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment. A systematic review based on numbers needed to treat. Cephalalgia 1998;18:532-8